Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T12:51:04.303Z.
Calculation as of: 2026-10-06T12:51:04.303Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ea268c636d02c1563f9a0cc17fa45ef3048b6802d4031696aa30e1bc9d7aaf2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Connect Biopharma Holdings Limited
Market Cap
$56.54M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$52.95M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$60.29M
EV/Sales Ratio
N/A
TTM Avg
10156.67x
3Y Avg
5697.35x
5Y Avg
5697.35x
Market Cap
$51.58M
EV/Sales Ratio
N/A
TTM Avg
768.07x
3Y Avg
1353.01x
5Y Avg
2660.76x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Connect Biopharma Holdings Limited (CNTB) | $56.54M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $55.72M | N/A | 3.74x | 3.42x | 3.42x |
| Boundless Bio, Inc. (BOLD)vs › | $58.43M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | 46.89x | 17.85x | 13.82x |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.95M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $60.29M | N/A | 10156.67x | 5697.35x | 5697.35x |
| Adicet Bio, Inc. (ACET)vs › | $60.48M | N/A | 8.16x | 93.50x | 96.95x |
| MiNK Therapeutics, Inc. (INKT)vs › | $60.78M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.58M | N/A | 768.07x | 1353.01x | 2660.76x |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
